Does aspirin save lives in patients with COVID-19?
作者信息
Voruganti Dinesh, Bassareo Pier Paolo, Calcaterra Giuseppe, Mehta J L
机构信息
Division of Cardiology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland.
出版信息
Heart. 2022 Jan;108(2):88-89. doi: 10.1136/heartjnl-2021-320255. Epub 2021 Oct 16.
Abstract
摘要
相似文献
1
Does aspirin save lives in patients with COVID-19?阿司匹林对新冠患者有救命作用吗？
Heart. 2022 Jan;108(2):88-89. doi: 10.1136/heartjnl-2021-320255. Epub 2021 Oct 16.
2
COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.一系列阿司匹林加重性呼吸道疾病患者中的新型冠状病毒肺炎
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2900-2903. doi: 10.1016/j.jaip.2021.04.060. Epub 2021 May 18.
3
Aspirin Is Related to Worse Clinical Outcomes of COVID-19.阿司匹林与 COVID-19 患者的临床转归较差相关。
Medicina (Kaunas). 2021 Sep 4;57(9):931. doi: 10.3390/medicina57090931.
4
[SARS-CoV-2 Seroprevalence Among Healthcare Workers: Retrospective Analysis of the Data From A University Hospital in Turkey].[土耳其一家大学医院医护人员中新冠病毒血清流行率：回顾性数据分析]
Mikrobiyol Bul. 2021 Apr;55(2):223-232. doi: 10.5578/mb.20219908.
5
Comparison of SARS-CoV-2 infections in healthcare workers with high and low exposures to Covid-19 patients in a Norwegian University Hospital.挪威大学医院中接触新冠患者程度高与低的医护人员感染新冠病毒的比较。
Infect Dis (Lond). 2021 Jun;53(6):420-429. doi: 10.1080/23744235.2021.1885734. Epub 2021 Feb 23.
6
Risk of SARS-CoV-2 transmission from universally masked healthcare workers to patients or residents: A prospective cohort study.医护人员普遍戴口罩对患者或居民传播 SARS-CoV-2 的风险：一项前瞻性队列研究。
Am J Infect Control. 2021 Nov;49(11):1429-1431. doi: 10.1016/j.ajic.2021.08.024. Epub 2021 Aug 27.
7
[Antibody Screening and Risk Assessment of Healthcare Professionals in the COVID-19 Pandemic].[新冠疫情期间医护人员的抗体筛查与风险评估]
Mikrobiyol Bul. 2021 Jul;55(3):357-373. doi: 10.5578/mb.20219806.
8
Is Aspirin the True Protective Therapy in Coronavirus Disease 2019 Patients?阿司匹林是2019冠状病毒病患者真正的保护性治疗方法吗？
Anesth Analg. 2021 Sep 1;133(3):e41. doi: 10.1213/ANE.0000000000005635.
9
Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak.新冠疫情爆发后，对比利时一家拥有4个院区的公立医院医护人员进行大规模SARS-CoV-2分子和血清学筛查。
J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.07.033. Epub 2020 Jul 31.
10
Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study.BNT162b2 疫苗接种与 SARS-CoV-2 感染及与 covid-19 相关的住院和死亡的关联：在加泰罗尼亚的养老院和医护人员中的前瞻性队列研究。
BMJ. 2021 Aug 18;374:n1868. doi: 10.1136/bmj.n1868.
引用本文的文献
1
Control of type 2 diabetes in patients with cancer and chronic pro-inflammatory cytokines during the COVID-19 pandemic.2019冠状病毒病大流行期间癌症患者和慢性促炎细胞因子患者的2型糖尿病控制
J Med Life. 2025 May;18(5):428-439. doi: 10.25122/jml-2025-0061.
2
Development and Validation of an HPLC-UV Method for the Quantification of 4'-Hydroxydiclofenac Using Salicylic Acid: Future Applications for Measurement of In Vitro Drug-Drug Interaction in Rat Liver Microsomes.建立并验证了一种 HPLC-UV 方法，用于定量检测 4'-羟基双氯芬酸，使用水杨酸作为内标物：未来可用于检测大鼠肝微粒体中体外药物相互作用。
Molecules. 2022 Jun 2;27(11):3587. doi: 10.3390/molecules27113587.
3
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19.环氧合酶信号阻断可保护中年小鼠免受严重 COVID-19 影响。
Nature. 2022 May;605(7908):146-151. doi: 10.1038/s41586-022-04630-3. Epub 2022 Mar 21.
4
Heartbeat: the role of antiplatelet therapy in treatment of COVID-19 infections.心跳：抗血小板治疗在新冠病毒感染治疗中的作用
Heart. 2022 Jan;108(2):83-85. doi: 10.1136/heartjnl-2021-320691.
本文引用的文献
1
Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry.抗血小板治疗与 COVID-19 结局：健康结局预测评估登记。
Heart. 2022 Jan;108(2):130-136. doi: 10.1136/heartjnl-2021-319552. Epub 2021 Oct 5.
2
Surviving Covid-19 with Heparin?使用肝素治疗新冠病毒肺炎能否存活？
N Engl J Med. 2021 Aug 26;385(9):845-846. doi: 10.1056/NEJMe2111151. Epub 2021 Aug 4.
3
Pre-hospital antiplatelet medication use on COVID-19 disease severity.COVID-19 疾病严重程度与院前抗血小板药物的使用。
Heart Lung. 2021 Sep-Oct;50(5):618-621. doi: 10.1016/j.hrtlng.2021.04.010. Epub 2021 May 27.
4
COVID-19 mortality in patients on anticoagulants and antiplatelet agents.使用抗凝剂和抗血小板药物的患者的新冠病毒疾病死亡率
Br J Haematol. 2020 Aug;190(4):e192-e195. doi: 10.1111/bjh.16968. Epub 2020 Jul 19.
5
Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study.住院 COVID-19 患者入院前抗栓治疗的临床影响：一项多中心观察性研究。
Pharmacol Res. 2020 Sep;159:104965. doi: 10.1016/j.phrs.2020.104965. Epub 2020 May 29.
6
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.强化血小板抑制治疗可改善严重 COVID-19 合并高凝状态患者的低氧血症：一项病例对照、概念验证研究。
Pharmacol Res. 2020 Aug;158:104950. doi: 10.1016/j.phrs.2020.104950. Epub 2020 May 23.
7
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.双嘧达莫对重症 COVID-19 患者的潜在治疗作用。
Acta Pharm Sin B. 2020 Jul;10(7):1205-1215. doi: 10.1016/j.apsb.2020.04.008. Epub 2020 Apr 20.
Zotero 插件